Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan

H. Niiya, Y. Kanda, T. Saito, T. Ohnishi, S. Kanai, Y. Kawano, K. Kamijo, A. Iizuka, K. Yakushuin, K. Ueda, A. Chizuka, K. Idima, M. Ohnishi, K. Nakai, A. Makimoto, Ryuji Tanosaki, K. Tobinai, H. Wakasugi, Y. Takaue, S. Mineishi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background and Objectives. The aim of this study was to evaluate lineage-specific chimerism reconstitution after reduced-intensity allogeneic stem cell transplantation (RIST) using a combination of fludarabine (30 mg/m2 for 6 days) and busulfan (4 mg/kg for 2 days). Design and Methods. We prospectively enrolled 8 consecutive patients with hematologic malignancies who were not candidates for conventional transplantation because of either high age or organ dysfunction. Host-donor chimerism was evaluated using polymerase chain reaction-based amplification of a polymorphic short tandem repeat region. Results. All of our patients achieved engraftment within a median of 11 days after transplantation. On day 30, full donor myeloid cell chimerism (<90%) was achieved in 7 patients whereas full donor T-cell chimerism was achieved in only one patient. Thus, in contrast to other reported results, full donor chimerism was achieved earlier in the myeloid lineage than the T-cell lineage. On day 60, however, T-cell chimerism caught up with myeloid chimerism. Two patients developed grade II-IV acute graft-versus-host disease (GVHD) before the detection of full donor T-cell chimerism. Interpretation and Conclusions. Our findings suggest that the kinetics of lineage-specific chimerism depend on the agents used in the conditioning regimen, and may provide insight into the chimerism kinetics and pathogenesis of GVHD. Thus, the strategy for controlling immunosuppression after RIST should be modified according to the type of conditioning regimen applied.

Original languageEnglish
Pages (from-to)1071-1074
Number of pages4
JournalHaematologica
Volume86
Issue number10
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Busulfan
Chimerism
Stem Cell Transplantation
Tissue Donors
T-Lymphocytes
Graft vs Host Disease
Transplantation
fludarabine
Cell Lineage
Hematologic Neoplasms
Myeloid Cells
Microsatellite Repeats
Immunosuppression

Keywords

  • Busulfan
  • Chimerism
  • Fludarabine
  • Reduced-intensity stem cell transplantation
  • Short tandem repeat

ASJC Scopus subject areas

  • Hematology

Cite this

Niiya, H., Kanda, Y., Saito, T., Ohnishi, T., Kanai, S., Kawano, Y., ... Mineishi, S. (2001). Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Haematologica, 86(10), 1071-1074.

Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. / Niiya, H.; Kanda, Y.; Saito, T.; Ohnishi, T.; Kanai, S.; Kawano, Y.; Kamijo, K.; Iizuka, A.; Yakushuin, K.; Ueda, K.; Chizuka, A.; Idima, K.; Ohnishi, M.; Nakai, K.; Makimoto, A.; Tanosaki, Ryuji; Tobinai, K.; Wakasugi, H.; Takaue, Y.; Mineishi, S.

In: Haematologica, Vol. 86, No. 10, 2001, p. 1071-1074.

Research output: Contribution to journalArticle

Niiya, H, Kanda, Y, Saito, T, Ohnishi, T, Kanai, S, Kawano, Y, Kamijo, K, Iizuka, A, Yakushuin, K, Ueda, K, Chizuka, A, Idima, K, Ohnishi, M, Nakai, K, Makimoto, A, Tanosaki, R, Tobinai, K, Wakasugi, H, Takaue, Y & Mineishi, S 2001, 'Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan', Haematologica, vol. 86, no. 10, pp. 1071-1074.
Niiya, H. ; Kanda, Y. ; Saito, T. ; Ohnishi, T. ; Kanai, S. ; Kawano, Y. ; Kamijo, K. ; Iizuka, A. ; Yakushuin, K. ; Ueda, K. ; Chizuka, A. ; Idima, K. ; Ohnishi, M. ; Nakai, K. ; Makimoto, A. ; Tanosaki, Ryuji ; Tobinai, K. ; Wakasugi, H. ; Takaue, Y. ; Mineishi, S. / Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. In: Haematologica. 2001 ; Vol. 86, No. 10. pp. 1071-1074.
@article{93df7afd44704a0eb7da9563580c4fdf,
title = "Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan",
abstract = "Background and Objectives. The aim of this study was to evaluate lineage-specific chimerism reconstitution after reduced-intensity allogeneic stem cell transplantation (RIST) using a combination of fludarabine (30 mg/m2 for 6 days) and busulfan (4 mg/kg for 2 days). Design and Methods. We prospectively enrolled 8 consecutive patients with hematologic malignancies who were not candidates for conventional transplantation because of either high age or organ dysfunction. Host-donor chimerism was evaluated using polymerase chain reaction-based amplification of a polymorphic short tandem repeat region. Results. All of our patients achieved engraftment within a median of 11 days after transplantation. On day 30, full donor myeloid cell chimerism (<90{\%}) was achieved in 7 patients whereas full donor T-cell chimerism was achieved in only one patient. Thus, in contrast to other reported results, full donor chimerism was achieved earlier in the myeloid lineage than the T-cell lineage. On day 60, however, T-cell chimerism caught up with myeloid chimerism. Two patients developed grade II-IV acute graft-versus-host disease (GVHD) before the detection of full donor T-cell chimerism. Interpretation and Conclusions. Our findings suggest that the kinetics of lineage-specific chimerism depend on the agents used in the conditioning regimen, and may provide insight into the chimerism kinetics and pathogenesis of GVHD. Thus, the strategy for controlling immunosuppression after RIST should be modified according to the type of conditioning regimen applied.",
keywords = "Busulfan, Chimerism, Fludarabine, Reduced-intensity stem cell transplantation, Short tandem repeat",
author = "H. Niiya and Y. Kanda and T. Saito and T. Ohnishi and S. Kanai and Y. Kawano and K. Kamijo and A. Iizuka and K. Yakushuin and K. Ueda and A. Chizuka and K. Idima and M. Ohnishi and K. Nakai and A. Makimoto and Ryuji Tanosaki and K. Tobinai and H. Wakasugi and Y. Takaue and S. Mineishi",
year = "2001",
language = "English",
volume = "86",
pages = "1071--1074",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "10",

}

TY - JOUR

T1 - Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan

AU - Niiya, H.

AU - Kanda, Y.

AU - Saito, T.

AU - Ohnishi, T.

AU - Kanai, S.

AU - Kawano, Y.

AU - Kamijo, K.

AU - Iizuka, A.

AU - Yakushuin, K.

AU - Ueda, K.

AU - Chizuka, A.

AU - Idima, K.

AU - Ohnishi, M.

AU - Nakai, K.

AU - Makimoto, A.

AU - Tanosaki, Ryuji

AU - Tobinai, K.

AU - Wakasugi, H.

AU - Takaue, Y.

AU - Mineishi, S.

PY - 2001

Y1 - 2001

N2 - Background and Objectives. The aim of this study was to evaluate lineage-specific chimerism reconstitution after reduced-intensity allogeneic stem cell transplantation (RIST) using a combination of fludarabine (30 mg/m2 for 6 days) and busulfan (4 mg/kg for 2 days). Design and Methods. We prospectively enrolled 8 consecutive patients with hematologic malignancies who were not candidates for conventional transplantation because of either high age or organ dysfunction. Host-donor chimerism was evaluated using polymerase chain reaction-based amplification of a polymorphic short tandem repeat region. Results. All of our patients achieved engraftment within a median of 11 days after transplantation. On day 30, full donor myeloid cell chimerism (<90%) was achieved in 7 patients whereas full donor T-cell chimerism was achieved in only one patient. Thus, in contrast to other reported results, full donor chimerism was achieved earlier in the myeloid lineage than the T-cell lineage. On day 60, however, T-cell chimerism caught up with myeloid chimerism. Two patients developed grade II-IV acute graft-versus-host disease (GVHD) before the detection of full donor T-cell chimerism. Interpretation and Conclusions. Our findings suggest that the kinetics of lineage-specific chimerism depend on the agents used in the conditioning regimen, and may provide insight into the chimerism kinetics and pathogenesis of GVHD. Thus, the strategy for controlling immunosuppression after RIST should be modified according to the type of conditioning regimen applied.

AB - Background and Objectives. The aim of this study was to evaluate lineage-specific chimerism reconstitution after reduced-intensity allogeneic stem cell transplantation (RIST) using a combination of fludarabine (30 mg/m2 for 6 days) and busulfan (4 mg/kg for 2 days). Design and Methods. We prospectively enrolled 8 consecutive patients with hematologic malignancies who were not candidates for conventional transplantation because of either high age or organ dysfunction. Host-donor chimerism was evaluated using polymerase chain reaction-based amplification of a polymorphic short tandem repeat region. Results. All of our patients achieved engraftment within a median of 11 days after transplantation. On day 30, full donor myeloid cell chimerism (<90%) was achieved in 7 patients whereas full donor T-cell chimerism was achieved in only one patient. Thus, in contrast to other reported results, full donor chimerism was achieved earlier in the myeloid lineage than the T-cell lineage. On day 60, however, T-cell chimerism caught up with myeloid chimerism. Two patients developed grade II-IV acute graft-versus-host disease (GVHD) before the detection of full donor T-cell chimerism. Interpretation and Conclusions. Our findings suggest that the kinetics of lineage-specific chimerism depend on the agents used in the conditioning regimen, and may provide insight into the chimerism kinetics and pathogenesis of GVHD. Thus, the strategy for controlling immunosuppression after RIST should be modified according to the type of conditioning regimen applied.

KW - Busulfan

KW - Chimerism

KW - Fludarabine

KW - Reduced-intensity stem cell transplantation

KW - Short tandem repeat

UR - http://www.scopus.com/inward/record.url?scp=0034756716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034756716&partnerID=8YFLogxK

M3 - Article

C2 - 11602413

AN - SCOPUS:0034756716

VL - 86

SP - 1071

EP - 1074

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 10

ER -